Correlation Between PulteGroup, and CRISPR Therapeutics

Can any of the company-specific risk be diversified away by investing in both PulteGroup, and CRISPR Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining PulteGroup, and CRISPR Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between PulteGroup, and CRISPR Therapeutics AG, you can compare the effects of market volatilities on PulteGroup, and CRISPR Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in PulteGroup, with a short position of CRISPR Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of PulteGroup, and CRISPR Therapeutics.

Diversification Opportunities for PulteGroup, and CRISPR Therapeutics

-0.04

Correlation Coefficient

PulteGroup,  CRISPR Therapeutics

Good diversification

The 3 months correlation between PulteGroup, and CRISPR is -0.04. Overlapping area represents the amount of risk that can be diversified away by holding PulteGroup, and CRISPR Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CRISPR Therapeutics and PulteGroup, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on PulteGroup, are associated (or correlated) with CRISPR Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CRISPR Therapeutics has no effect on the direction of PulteGroup, i.e., PulteGroup, and CRISPR Therapeutics go up and down completely randomly.

Pair Corralation between PulteGroup, and CRISPR Therapeutics

Assuming the 90 days trading horizon PulteGroup, is expected to under-perform the CRISPR Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, PulteGroup, is 2.23 times less risky than CRISPR Therapeutics. The stock trades about -0.17 of its potential returns per unit of risk. The CRISPR Therapeutics AG is currently generating about -0.01 of returns per unit of risk over similar time horizon. If you would invest  3,159  in CRISPR Therapeutics AG on December 26, 2024 and sell it today you would lose (219.00) from holding CRISPR Therapeutics AG or give up 6.93% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	98.36%
Values	Daily Returns

PulteGroup,  vs.  CRISPR Therapeutics AG

PulteGroup,

Risk-Adjusted Performance

Very Weak

Over the last 90 days PulteGroup, has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's technical indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

CRISPR Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days CRISPR Therapeutics AG has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, CRISPR Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with PulteGroup, and CRISPR Therapeutics

The main advantage of trading using opposite PulteGroup, and CRISPR Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if PulteGroup, position performs unexpectedly, CRISPR Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will offset losses from the drop in CRISPR Therapeutics' long position.

The idea behind PulteGroup, and CRISPR Therapeutics AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.